Latent TB infection in children and adolescents: Scientific rationale and programmatic management

Indian J Tuberc. 2023:70 Suppl 1:S35-S38. doi: 10.1016/j.ijtb.2023.09.001. Epub 2023 Sep 6.

Abstract

As we march towards the goals of TB elimination, one area of focus is on TB preventive therapy which deals with treatment of latent TB infection, the pool from which future TB cases are generated. Children are particularly vulnerable to disseminated TB and seriously ill TB like TB meningitis, which highlights the need for addressing latent TB infection in the age group of 0-18 years. The national TB elimination program has extended it's strategy to include TB preventive therapy from treating children <5 years and PLHIV to treating children ≥5 years, adolescents and adult household contacts of TB cases and at risk immunosuppressed groups. Newer regimens including weekly INH and Rifapentine for three months (3HP) has been recommended in the program. Concerns and opportunities for operational research in this area include surveillance and monitoring for drug toxicity and resistance, strategies to ensure adherence and improve treatment completion and outcomes.

Keywords: Infection; LTBI; Latent; TB; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / therapeutic use
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Humans
  • Infant
  • Infant, Newborn
  • Isoniazid / therapeutic use
  • Latent Tuberculosis* / diagnosis
  • Latent Tuberculosis* / drug therapy
  • Latent Tuberculosis* / prevention & control
  • Tuberculosis, Meningeal* / drug therapy

Substances

  • Antitubercular Agents
  • Isoniazid